SAIFU: Nonclinical Research and 2026 Developments

Summary

SAIFU disclosed Hebei GLP recertification, a Wuxi radiopharmaceutical platform and a September anniversary event. This review distinguishes entities, facilities and study scope.

Source Scope

Information checked as of 14 October 2026. This report reviews dated company news, the company's English identity and Wuxi government materials. Laboratory developments are attributed to the relevant subsidiary or facility. Company certification announcements remain company disclosures; certificate scope, validity and study eligibility require checks against the issuing authority's records.

Services and Industry-chain Role

Beijing Safe Institute of Pharmaceutical Research Co., Ltd. operates under the SAIFU brand. Its 2026 news emphasizes nonclinical research and describes quality systems and service directions at the Hebei and Wuxi platforms. [1][2] The company's English website identifies the legal name in its copyright notice. [5]

For a contract research organization, value is delivered through study design, laboratory execution, bioanalysis, data quality and submission-ready documentation. A group-level description should be connected to the actual contracting entity and facility; it cannot substitute for a laboratory's authorization.

Service Workflow and Business Analysis

A nonclinical study needs an identified test article, research objective, test system, administration plan, analytical methods and intended use of the report. Procurement review should connect the contracting entity, protocol, facilities, validated methods, raw records and final report. Quality systems affect both traceability and the purposes for which a customer can use the evidence.

Radiopharmaceutical research also requires attention to radioactive-material use, isotope and facility permissions, personnel protection and sample handling. A Wuxi High-tech District government article dated 19 May 2025 identifies the local SAIFU platform within the radiopharmaceutical service chain and describes its laboratory and nonclinical evaluation role. [4] That source supports business positioning, without confirming every potential study type.

Verified 2026 Developments

On 21 April 2026, the company website reported GLP certification for the Wuxi subsidiary and described its radiopharmaceutical evaluation direction. [2] This development concerns the Wuxi entity, rather than a new authorization covering every activity of the Beijing entity.

On 4 June 2026, the website reported that the wholly owned Hebei subsidiary completed an NMPA GLP recertification site inspection on 3 June. The company described this as its third certification after 2020 and 2023, covering ten qualification categories. [1] A site inspection, a certificate and eligibility for a particular research project are distinct evidence levels. Certificate originals and current scope should be checked before commissioning work.

On 12 September 2026, company news recorded a tenth-anniversary event in Suzhou and discussed technical iteration, international business and talent development. [3] The event is a dated 2026 development. The article did not provide audited figures sufficient to quantify the revenue or profit growth it discussed.

Competitive Position and Delivery

The Hebei recertification report and Wuxi radiopharmaceutical direction offer concrete ways to examine specialization. The analytical question is whether customers can access suitable facilities, execute agreed protocols and receive complete evidence. Geographic coverage alone does not establish delivery efficiency.

Comparable indicators include authorized study types, current certificates, scheduling, method transfer, data integrity and review records. The sources did not establish comparable order volumes, retention rates or margins, so no market ranking or growth estimate is made.

Resource Direction

The 2026 disclosures focus on laboratory quality systems, a radiopharmaceutical platform and professional staff. As an analytical judgment, new molecular types and radiopharmaceutical projects place substantial demands on method development and compliance. Commercial results depend on matching projects to validated capabilities and sustained customer use.

The roles of the group, the Beijing entity, the Hebei subsidiary and the Wuxi subsidiary should remain explicit in contracts and evidence review. Certifications belong to specific facilities and scopes; combining references from several facilities cannot establish the complete capability of a single entity.

Variables to Follow

Useful subsequent evidence would include current certificate scopes, radiopharmaceutical study deliveries, validated methods and preparation of data for international submissions. Clear connections between entity, facility and study purpose make the disclosed platform strategy more assessable.

Public-source References

• 1. Company news: Hebei GLP recertification disclosure; 4 June 2026, Chinese source
• 2. Company news: Wuxi radiopharmaceutical GLP disclosure; 21 April 2026, Chinese source
• 3. Company news: tenth-anniversary event; 12 September 2026, Chinese source
• 4. Wuxi High-tech District: radiopharmaceutical meeting; 19 May 2025, Chinese source
• Company website

Research Boundary

This report is based on company disclosures and government materials. It does not constitute investment advice, commercial endorsement, a promise of registration success or a determination of Little Giant recognition. A certification announcement does not guarantee regulatory acceptance of a particular project. Undisclosed financial results, orders and customer composition are not estimated.